AI国产自免双抗！进入2期临床

Core Viewpoint - The National Medical Products Administration has approved the initiation of Phase II clinical trials for AK139, a dual-specific antibody targeting IL-4Rα/ST2, developed by Kangfang Biotech (9926.HK), for seven indications [1][4] Group 1: Clinical Development - AK139 is set to undergo clinical trials for chronic obstructive pulmonary disease, severe bronchial asthma, chronic spontaneous urticaria, allergic rhinitis, chronic sinusitis with nasal polyps, moderate to severe atopic dermatitis, and nodular prurigo [1][4] - This marks the first global approval for a dual-specific antibody targeting IL-4Rα/ST2, indicating a significant advancement in the treatment of respiratory and autoimmune diseases [1][4] Group 2: Innovation and Technology - The development of AK139 leverages Kangfang's proprietary AI drug development technology, showcasing the company's commitment to innovation in the pharmaceutical sector [1][4] - The introduction of AK139 represents a strategic expansion of Kangfang Biotech's dual/multi-antibody drug development capabilities from oncology to other therapeutic areas [1][4]